Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 16, Issue 6, 1998, Pages 2133-2141

  Giaccone, Giuseppe ^a   Splinter, Ted A ^a   Debruyne, Channa ^a   Kho, Gwan S ^a   Lianes, Pilar ^a   Van Zandwijk, Nico ^a   Pennucci, Maria Cristina ^a   Scagliotti, Giorgio ^a   Van Meerbeeck, Jan ^a   Van Hoesel, Quirinus ^a   Curran, Desmond ^a   Sahmoud, Tarek ^a   Postmus, Piet E ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; ONDANSETRON; PACLITAXEL; TENIPOSIDE;

ADULT; ADVANCED CANCER; AGED; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; ECHOGRAPHY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; THORAX RADIOGRAPHY; TREATMENT OUTCOME;

EID: 0031779533     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.6.2133     Document Type: Article

References (28)

1. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899-909, 1995
2. Giaccone G: New drugs for the management of lung cancer. Br J Hosp Med 55:634-638, 1996
3. Giaccone G, Donadio M, Ferrati P, et al: Teniposide (VM26) in the treatment of non-small cell lung carcinoma. Cancer Treat Rep 71:83-85, 1987
4. Splinter TAW, Sahmoud T, Festen J, et al: Two schedules of teniposide with or without cisplatin in advanced non-small cell lung cancer. A randomized study of the EORTC Lung Cancer Cooperative Group. J Clin Oncol 14:127-134, 1996
5. WHO: Handbook for Reporting Results of Cancer Treatment. Publication no. 48. Geneva, Switzerland, World Health Organization, 1979
6. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 31:103-115, 1975
7. Postmus PE, Giaccone G, Debruyne C, et al: Results of the phase II EORTC study comparing paclitaxel/cisplatin with teniposide/ cisplatin in patients with non-small cell lung cancer. Semin Oncol 23:10-13, 1996 (suppl 12)
8. Freedman LS: Tables of the number of patients required in clinical trials using the logrank test. Stat Med 1:121-129, 1982
9. Cox DR: Regression models and life-tables. J RStat Soc B 34:187-202, 1972
10. Albain KS, Crowley JJ, LeBlanc M, et al: Survival determinants in extensive-disease non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 9:1618-1626, 1991
11. Slevin ML, Clark PI, Joel SP, et al: A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J Clin Oncol 7:1333-1340, 1989
12. Bonomi P, Kim K, Chang A, et al: Phase III trial comparing etoposide (E) cisplatin (C) versus Taxol (T) with cisplatin-G-CSF (G) versus Taxol-cisplatin in advanced non-small cell lung cancer. An Eastern Cooperative Oncology Group (ECOG) trial. Proc Am Soc Clin Oncol 15:382, 1996 (abstr 1145)
13. Bonomi P, Kim K, Kugler J, et al: Comparison of survival for stage IIIB versus stage IV non-small cell lung cancer (NSCLC) patients treated with etoposide-cisplatin versus Taxol-cisplatin: An Eastern Cooperative Oncology Group (ECOG) trial. Proc Am Soc Clin Oncol 16:454a, 1997 (abstr 1631)
14. Seidman AD, Hochhauser D, Gullob M, et al: Ninety-six-hour paclitaxel infusion after progression during short taxane exposure: A phase II pharmacokinetic and pharmacodynamic study in metastatic cancer. J Clin Oncol 14:1877-1884, 1996
15. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
16. Piccart MJ, Bertelsen K, Stuart G, et al: Is cisplatin-paclitaxel (P-T) the standard in first-line treatment of advanced ovarian cancer (Ov Ca)? The EORTC-GCCG, NOCOVA, NCI-C and Scottish intergroup experience. Proc Am Soc Clin Oncol 16:352a, 1997 (abstr 1258)
17. Nabholtz JM, Gelmon K, Bontenbal M, et al: Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 14:1858-1867, 1996
18. Johnson DH, Paul DM, Hande KR, et al: Paclitaxel plus carboplatin in advanced non-small cell lung cancer: A phase II trial. J Clin Oncol 14:2054-2060, 1996
19. Giaccone G, Huizing M, Postmus PE, et al: Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer. Semin Oncol 22:78-82, 1995 (suppl 9)
20. Hoffman PC, Masters GA, Drinkard LC, et al: Ifosfamide plus paclitaxel in advanced non-small cell lung cancer; A phase I study. Ann Oncol 7:314-316, 1996
21. Shepherd FA, Letreille J, Crump M, et al: Phase I study of paclitaxel (Taxol) and ifosfamide in previously untreated patients with advanced non-small cell lung cancer. A study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 7:311-313, 1996
22. Klastersky J, Sculier JP: Dose-finding study of paclitaxel (Taxol) plus cisplatin in patients with non-small cell lung cancer. Lung Cancer 12:S117-S125, 1995 (suppl 2)
23. Langer CJ, Leighton JC, Comis RL, et al: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 13:1860-1870, 1995
24. Bunn PA: The North American experience with paclitaxel combined with cisplatin or carboplatin in lung cancer. Semin Oncol 23:18-25, 1996 (suppl 16)
25. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
26. Cella D, Fairclough DL, Bonomi PB, et al: Quality of life (QOL) in advanced non-small cell lung cancer (NSCLC): Results from Eastern Cooperative Oncology Group (ECOG) study E5592. Proc Am Soc Clin Oncol 16:2a, 1997 (abstr 4)
27. Crino' L, Scagliotti G, Marangolo M, et al: Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study. J Clin Oncol 15:297-303, 1997
28. Cardenal F, Rosell R, Anton A, et al: Gemcitabine + cisplatin versus etoposide + cisplatin in advanced non-small cell lung cancer patients: Preliminary randomized phase III results. Proc Am Soc Clin Oncol 16:458a, 1997 (abstr 1648)